UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 5.743

Sortiert nach

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2019-01, Vol.37 (3), p.190-201

2019

Volltextzugriff (PDF)

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

Investigational new drugs, 2019-04, Vol.37 (2), p.297-306

2019

Volltextzugriff (PDF)

Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma

Cancer, 2016-02, Vol.122 (4), p.559-564

2016

Volltextzugriff (PDF)

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

Blood, 2015-08, Vol.126 (7), p.863-872

2015

Volltextzugriff (PDF)

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

British journal of haematology, 2016-11, Vol.175 (4), p.631-640

2016

Volltextzugriff (PDF)

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Clinical cancer research, 2019-02, Vol.25 (4), p.1174-1184

2019

Volltextzugriff (PDF)

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Blood, 2020-03, Vol.135 (11), p.804-813

2020

Volltextzugriff (PDF)

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

The New England journal of medicine, 2002-06, Vol.346 (25), p.1937-1947

2002

Volltextzugriff (PDF)

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Blood, 2007-03, Vol.109 (5), p.1857-1861

2007

Volltextzugriff (PDF)

Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

The New England journal of medicine, 2004-04, Vol.350 (18), p.1828-1837

2004

Volltextzugriff (PDF)

Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5

Blood, 2007-01, Vol.109 (2), p.478-485

2007

Volltextzugriff (PDF)

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

British journal of haematology, 2016-06, Vol.173 (6), p.867-875

2016

Volltextzugriff (PDF)

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5027-5033

2005

Volltextzugriff (PDF)

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Haematologica (Roma), 2010-08, Vol.95 (8), p.1342-1349

2010

Volltextzugriff (PDF)

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Blood, 2006-10, Vol.108 (8), p.2720-2725

2006

Volltextzugriff (PDF)

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3121-3127

2006

Volltextzugriff (PDF)

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

Blood, 2006-06, Vol.107 (11), p.4207-4213

2006

Volltextzugriff (PDF)

Multidisciplinary Diagnostic Approach in Intraocular Lymphoma Featuring Pseudo-hypopyon: Case Series and Literature Review

Ocular immunology and inflammation, 2021-04, Vol.29 (3), p.490-495

2021

Volltextzugriff (PDF)

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Blood, 2003-06, Vol.101 (11), p.4279-4284

2003

Volltextzugriff (PDF)

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood, 2019-09, Vol.134 (11), p.851-859

2019

Volltextzugriff (PDF)

Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas

Blood, 2012-05, Vol.119 (21), p.4838-4844

2012

Volltextzugriff (PDF)

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

Annals of oncology, 2006-01, Vol.17 (1), p.123-130

2006

Volltextzugriff (PDF)

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Blood, 2003-06, Vol.101 (12), p.4653-4659

2003

Volltextzugriff (PDF)

1 – 25 von 5.743

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.134)
Mit Volltextzugriff
(4.551)

Publikationsform

Artikel
(5.742)
magazinearticle
(1)

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(5.743)
Male
(4.738)
Science & Technology
(4.686)
Life Sciences & Biomedicine
(4.637)
Female
(4.450)
Aged
(3.598)
Adult
(3.280)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(2.684)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2.435)
Oncology
(2.344)
Hematology
(1.969)
Treatment Outcome
(1.769)
Medical Sciences
(1.707)
Biological And Medical Sciences
(1.706)
Aged, 80 And Over
(1.679)
Rituximab
(1.426)
Prognosis
(1.295)
Hematologic And Hematopoietic Diseases
(1.224)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(1.197)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

Multidisciplinary Diagnostic Approach in Intraocular Lymphoma Featuring Pseudo-hypopyon: Case Series and Literature Review

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Aktive Filter

Suchergebnisse filtern